Overview

Combination Chemotherapy in Treating Women With Resected Breast Cancer

Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them after surgery may kill any tumor cells remaining after surgery. It is not yet known which combination chemotherapy regimen is more effective in treating resected stage I or stage II breast cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating women who have resected stage I or stage II breast cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Institute of Cancer Research, United Kingdom
Treatments:
Cyclophosphamide
Docetaxel
Epirubicin
Fluorouracil
Methotrexate
Tamoxifen